Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 18 filings·Updated 22 Sept 2026
Showing 10 of 18 filings.
22 Sept 20262 filings
Company UpdateGeneral

Jenburkt Pharmaceuticals shares admitted to NSE 'Permitted to Trade' category from 17 August 2026

Admission to NSE 'Permitted to Trade' category

  • NSE circular permits Jenburkt's equity shares to trade under 'Permitted to Trade' from 17 Aug 2026.
  • The company has not applied for NSE listing; shares remain listed on BSE.
  • No separate communication was received from NSE; the company learned of the circular later.
  • Trading on NSE does not affect governance, capital structure, or the company's listing status.
  • This intimation is for information and records of exchange, shareholders, and stakeholders.
Filed 13:20View Source
Insider Trading / SASTClosure of Trading Window

Jenburkt Pharmaceuticals Limited trading window closed from 1st October, 2026 till 48 hours after the price sensitive information viz. standalone unaudited financial results, pertaining to the quarter and half year ending on 30th September, 2026, a re disseminated or made public.

Jenburkt Pharmaceuticals Limited trading window closed from 1st October, 2026 till 48 hours after the price sensitive information viz. standalone unaudited financial results, pertaining to the quarter and half year ending on 30th September, 2026, a re disseminated or made public.

Filed 13:04View Source
18 Sept 20261 filing
Company UpdateChange in Management

Jenburkt Pharmaceuticals reports resignation of Senior VP International Business effective 18 September 2026

Resignation of SMP – International Business

  • Resignation of Vinay Bhatt, Sr. VP – International Business, effective 18 September 2026, due to personal reasons.
Filed 16:23View Source
7 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication for standalone Unaudited Financial Results for the quarter ended on 30th June, 2026.

No brief for this announcement.Newspaper publications aren’t summarised. View the original using the link below
Filed 11:41View Source
6 Aug 20261 filing
ResultFinancial Results

Jenburkt Pharmaceuticals Q1 FY2027 standalone results: revenue ₹3,551.20 lakhs, PAT ₹588.56 lakhs

Financial highlights

  • Revenue from operations ₹3,551.20 lakhs in Q1 FY2027, -0.04% YoY.
  • Total income ₹3,702.52 lakhs; YoY -1.35% to ₹3,758.39.
  • Total expenses ₹3,025.61 lakhs; QoQ down 3.60%.
  • PBT before tax ₹676.91 lakhs; QoQ down from ₹1,370.82.
  • Tax expense ₹88.35 lakhs; current ₹100.00, deferred -₹11.65.
  • Profit after tax ₹588.56 lakhs; YoY -24.5%.
  • EPS ₹13.34; Basic and Diluted for Q1 FY2027.
  • Total comprehensive income ₹738.81 lakhs.
  • Labour Codes impact ₹0 in Q1 FY2027; ₹395.11 lakhs in prior quarter.
  • Pharma segment only; no segment-wise reporting.
  • Limited review by DR Mehta & Associates; not an audit.
Filed 20:05View Source
13 Jul 20261 filing
Company UpdateChange in Registered Office Address

Jenburkt Pharmaceuticals shifts registered office within Mumbai, effective 21 July 2026

Registered office change

  • From: Nirmala Apartments, 93 Jay Prakash Road, Andheri West, Mumbai 400 058.
  • To: 14th Floor, Unicorn, Dattaji Salvi Marg, off Veera Desai Road, Andheri West, Mumbai 400 053.
  • Effective from 21 July 2026.
  • Within Mumbai city; ROC unchanged.
  • Board approval via circular resolution dated 13 July 2026.
  • Telephone, email and website unchanged.
Filed 18:43View Source
10 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jenburkt confirms dematerialisation processed through 30 June 2026; securities listed and records updated

Dematerialisation processing and listing

  • Dematerialisation requests up to 30 June 2026 were processed and listed on exchanges.
  • Physical certificates dematerialised were mutilated and cancelled; depository name updated within 15 days.
Filed 15:53View Source
14 Apr 20261 filing
Company UpdateGeneral

Pursuant to SEBI Circular dated 10th August, 2021, we hereby confirm that, for the financial year ended 31st March, 2026, Jenburkt pharmaceuticals Limited is "not a large corporate" as ....

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 13:18View Source
7 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations 2018 for the quarter ended on 31-03-2026.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 12:11View Source
23 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

Intimation of closure of trading window of Jenburkt Phamaceuticals Limited as per SEBI(Prohibition of Insider Trading) Regulations, 2015.

No brief for this announcement.This type of announcement aren’t summarised. View the original using the link below
Filed 13:11View Source
Showing 10 of 18 filings